A+ A A-

What's New

New to Portal

  • Demonstrate expertise in medical and public health microbiology with ABMM certification; application deadline August 1.
    02-24-2015

  • ASM together with CAP and CLSI are coordinating preparation of materials to help you address the CMS requirement for implementation...
    02-19-2015

  • A popular feature of the Journal of Clinical Microbiology. A new quiz is now posted.
    02-09-2015

  • New CDC Guidance: The first of two for managing clinical specimens for tests other than Ebola.
    02-04-2015

  • ASM's February Hot Topic, "Optimizing Laboratory Test Utilization in Microbiology and Beyond" is presented by...
    02-02-2015

ASM Updates

News Digest

Public Policy

Upcoming Events

Career Connections


Featured Content

  • Update: 8 O.C. measles cases now confirmed in Disneyland outbreak

    Update: 8 O.C. measles cases now confirmed in Disneyland outbreak

    The number of Orange County residents who contracted measles after visiting Disneyland Resort in December now stands at eight, and public health officials said they expected the number to keep climbing. Three were children who weren’t vaccinated against the highly contagious disease, according to the Orange County Health Care Agency. The other five were adults, only two of whom had the recommended number of doses of the vaccine.

  • Ebola Virus: a Clear and Present Danger

    Ebola Virus: a Clear and Present Danger

    An epidemic of Ebola virus disease is occurring in Western Africa on a scale not seen before, particularly in the countries of Guinea, Liberia, and Sierra Leone. The continued spread is facilitated by insufficient medical facilities, poor sanitation, travel, and unsafe burial practices. Several patients diagnosed with Ebola virus disease in Africa have been evacuated to the United States for treatment, and several other patients have been diagnosed in the United States. It is important for laboratories to be aware of available tests, especially those granted emergency use authorization, as hospitals prepare protocols for the diagnosis and management of high-risk patients

  • Researchers Develop Simoa-based Assay for Dengue Fever Host Immune Response

    Researchers Develop Simoa-based Assay for Dengue Fever Host Immune Response

    A team from Tufts University has published a proof of concept demonstrating that Quanterix's digital ELISA technology, Simoa, may allow more sensitive detection of the host immune response to dengue fever than other current methods. In the study, published this week online as an accepted manuscript in the Journal of Clinical Microbiology, the Tufts group described their development of a Simoa-based assay to detect type 2 anti-dengue IgG and IgM and compared its sensitivity to two commercially available ELISA kits for the two antibodies.


topics 10072014 qa 10072014 cumitechs 10072014 

Advertisement

American Society For Microbiology © 2015 | Privacy Policy | Terms of Use